Work

Figure 1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Year: 2025
Type: other
Abstract: RNA-seq of high-purity CTCs isolated from patients with metastatic prostate cancer reveals four transcriptional phenotypes. A, Tumor/CTC purity was assessed using the ESTIMATE algorithm in prostate cancer cell line samples (n = 12, green), CTC samples processed with standard-stringency (n = 41, blue) or novel high-stringency (n = 211, orange) method; healthy donor blood samples processed analogous to novel high-stringency CTC samples (n = 12, pink) and a published dataset of mCRPC tissue biopsies separated by biopsy site (n = 629, gray). ESTIMATE score is plotted for each sample. B, ESTIMATE tumor fraction (left) and CIBERSORTx immune content (right) scores for standard-stringency (n = 41, blue) or high-stringency (n = 211, orange) CTC methods are plotted and compared with prostate cancer cell lines (n = 12, green). C, Assessment of the number of samples meeting high-purity threshold for standard-stringency vs. high-stringency methods. D, Consensus k-means clustering of single-sample pathway z-scores of 146 high-purity CTC samples from 70 patients with metastatic prostate cancer identifies four distinct clusters. CRPC, castration-resistant prostate cancer.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4410047379
Cites:
Cited by:
Related to: 10